Share Email Print

Proceedings Paper

Clinical fluorescence diagnosis of human bladder carcinoma following low-dose photofrin injection
Author(s): Luc Baert M.D.; Roger Berg; B. van Damme; Marie-Ange D'Hallewin M.D.; Jonas Johansson; Katarina Svanberg M.D.; Sune Svanberg
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

A point-monitoring fluorescence diagnostic system based on a low-energy pulsed laser, fiber transmission optics, and an optical multichannel analyzer was used for diagnosis of patients with bladder malignancies. Twenty-four patients with bladder carcinoma, carcinoma in situ, and/or dysplasia were injected with Photofrin (0.35 or 0.5 mg/kg body weight) 48 hours prior to the investigation. The ratio between the red sensitizer emission and the bluish tissue autofluorescence provided excellent demarcation between papillary tumors and normal bladder wall. Certain cases of dysplasia could be also be differentiated from normal mucosa. Benign exofytic lesion such as malakoplakia appeared different from malignant tumors in fluorescence. Flat suspicious bladder mucosa such as that seen in infectious diseases or after radiation therapy appeared normal in terms of fluorescence.

Paper Details

Date Published: 1 November 1991
PDF: 6 pages
Proc. SPIE 1525, Future Trends in Biomedical Applications of Lasers, (1 November 1991); doi: 10.1117/12.48219
Show Author Affiliations
Luc Baert M.D., St. Pieter Univ. Hospital (Belgium)
Roger Berg, Lund Institute of Technology (Sweden)
B. van Damme, St. Rafael Univ. Hospital (Belgium)
Marie-Ange D'Hallewin M.D., St. Pieter Univ. Hospital (Belgium)
Jonas Johansson, Lund Institute of Technology (Sweden)
Katarina Svanberg M.D., Lund Univ. Hospital (Sweden)
Sune Svanberg, Lund Institute of Technology (Sweden)

Published in SPIE Proceedings Vol. 1525:
Future Trends in Biomedical Applications of Lasers
Lars Othar Svaasand, Editor(s)

© SPIE. Terms of Use
Back to Top